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Worldwide, every year nearly 15 million babies are born premature and out of them, 3.5 million are born in India, i.e., nearly 1/4th of the global prematurity burden 
is being handled by India itself [1,2]. Approximately 20% of them 
are either very low birth weight (LBW) (<1500 g) or very preterm 
(<33 weeks) who often have prolonged stay in neonatal intensive 
care unit (NICU) after birth due to prematurity and its associated 
complications. Epidemiological studies show that premature infants 
have an increased incidence and severity of vaccine-preventable 
diseases (VPD) such as pertussis, invasive pneumococcal diseases, 
and Haemophilus influenzae type b (HiB) [3-5]. The exact burden 
of VPD in lower and middle-income countries is not known.
Although several governing bodies have advised for timely 
vaccination of premature infants using the same schedule as 
recommended for full-term infants without any correction 
for prematurity and LBW, still their vaccination is often 
delayed [6-11]. Some of the notable reasons for this undue 
delay could be due to the lack of knowledge among health-care 
professionals (HCP) as well among parents regarding the safety 
and efficacy of vaccines in these premature infants. The concern 
could be due to the occurrence of adverse events such as fever, 
irritability, seizure, or risk increase in cardiorespiratory instability, 
e.g., apnea and tachycardia [12,13]. Hence, authors attempted to 
summarize the several practical issues on preterm vaccination for 
better understanding among HCP.
SEARCH STRATEGY
Since it is a narrative review, we conducted an informal search 
in PubMed/Medline using search words (vaccination OR 
immunisation OR immunization) AND (preterm OR premature 
OR “Very low birth weight” or “extreme low birth weight”) AND 
(infant OR baby OR neonate) with filter human and age of <1 year 
covering all literature updated until June 2019. From the available 
results, we included all landmark trials, observational studies 
(case–control, cohort study and cross-sectional), and excluded 
the case reports, case series, and review articles. We also searched 
internationally published guidelines on infant vaccination by 
various governing bodies for our purpose (e.g., American academy 
of Pediatrics (AAP), Centers for disease control and prevention 
(CDC) guideline, National Health Service guideline, and Redbook).
MYTHS AND FACTS ABOUT VACCINATION IN 
PRETERM INFANTS [6-8,14]
There are several concerns regarding vaccination in preterm NICU 
graduates among parents as well as HCP which are tabulated as 
Table 1.
EFFECT OF MATERNAL IMMUNITY ON 
VACCINATION IN PRETERM INFANTS [15-17]
In the early neonatal period, premature infants are prone to 
have infection from vaccine-preventable organisms due to their 
inadequate immunity. This limitation is partially compensated by 
transfer of maternal antibodies in fetal life. Thus, immunization 
of pregnant women against pathogens is a method of providing 
passive immunity to their future child in initial months of life. 
Transfer of antibodies depends on the various factors such as 
gestational age (higher toward later period of gestation), maternal 
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antibody level, type of immunoglobulin (Ig)G subclass (IgG1 has 
best permeability and IgG2 least [responsible of the recognition of 
polysaccharide antigens of encapsulated bacteria]), and placental 
characteristics (placental infection with malaria and HIV often 
prevents antibody transfer).
Studies have established the protective role of maternal 
vaccination for their infants in the initial 6 months due to passive 
placental transfer of antibodies. Therefore, the Government of India 
had introduced tetanus vaccine to all pregnant women in universal 
immunization program, which will soon be replaced by tetanus-
diphtheria (Td) vaccine, as per the WHO recommendations. In 
high-income countries, apart from tetanus vaccine, routinely 
administered vaccines during pregnancy period include acellular 
pertussis (aP) (in the form of Tdap) and influenza (trivalent 
influenza vaccine). Along with placental transfer of protective 
antibodies in the antenatal period, breast milk is an important 
source of Igs, immune cells, and immunogenic molecules. Apart 
from their protective effect against capsulated bacterial infections, 
maternal antibodies may interfere with antibody response to 
vaccines (especially measles) in infants younger than 6 months 
and limit their capacity to develop their own immune response 
against microorganisms. Hence, some vaccines like measles are 
administered only after 9 months of age.
NEONATAL IMMUNE SYSTEM [14,16-19]
1. Why NICU graduates are more vulnerable to VPD in infancy?
•	 During	the	intrauterine	period,	due	to	low	exposure	to	foreign	
antigens, the adaptive immunity in the newborn is primarily 
composed of lymphocytes. The production of antibodies 
by B cells begins a few months after birth. This limitation 
is partially compensated by passive transfer of maternal 
antibodies (IgG) through placenta, particularly in later 
gestation (3rd trimester). Thus, in premature infants, there is 
increased susceptibility to capsulated bacterial infection due 
to reduced transfer of maternal antibodies
•	 Among	 several	 IgG	 components,	 transplacental	 passage	 is	
highest for IgG1 and lowest for IgG2. However, IgG2 is the 
component, which provides protection against capsulated 
bacteria
•	 Most	of	the	preterm	infants	due	to	prematurity	itself	or	due	
to associated complications often have prolonged NICU stay; 
thus, there is more exposure to pathogenic organisms in early 
life
•	 Due	to	suboptimal	nutrition	and	postnatal	growth	retardation,	
preterm infants show suboptimal immune response
•	 Due	to	underlying	chronic	disorders	such	as	bronchopulmonary	
Table 1: Myths and facts about vaccination in preterm infants
Myths Facts
Vaccination in premature infants 
needs to be delayed as they are weak 
and frail
Although prematurity is associated with immunological immaturity, studies have shown that the uptake 
and immune response of most of the childhood vaccines are similar between preterm and full-term 
infants. Hence, vaccination should not be delayed and it should be done as per chronological age of the 
baby
Preterm immune response is 
inadequate to cause effective 
protection; hence, multiple extra 
doses might be required
Evidence has shown that commonly used vaccination schedule by several governing bodies is equally 
effective in providing adequate protection following primary vaccination series. Hence, apart from the 
routine booster doses as indicated for term infants, no extra doses of any vaccine are needed
Preterm neonates have more vaccine-
related adverse effects
Apart from adverse events related to underlying health conditions (apnea, bradycardia, and 
desaturations) which are more common in extremely preterm infants (<1000 g), incidence of classic 
vaccine-related adverse effects is similar to their term counterparts
Preterm neonates have associated 
comorbidities (BPD, feeding 
abnormality, and seizure)
Premature infants with associated comorbid conditions are at higher risk from VPD as compared to their 
healthier counterparts; hence, vaccination should be started in them as early as possible
Vaccines are painful for preterm 
neonates, and hence painless vaccine 
should be administered in them
The traditional term “painless vaccine” (combination vaccine containing aP component) is a misnomer 
created by manufacturers. Classically, aP component of DTaP vaccine is often attributed to less febrile 
reaction, thus, resulting in less irritability of babies which is interpreted as less pain. However, recent 
data support in favor of continue using whole-cell pertussis-containing vaccines for primary series in 
developing world due to acceptability, robust, and long-lasting immune response. Pentavalent vaccine 
(DTwP + HiB + Hep B) is available free of cost in government health-care facilities. Thus, choice of 
DPT versus DTaP should be individualized after discussing the facts with parents; choice of DTaP 
should not be merely due to prematurity
Preterm infants have less muscle 
mass; hence, it is difficult to give 
intramuscular vaccines to them
As preterm infants have less muscle mass, thin and shorter needle (5/8 inch) should be used
It is better to avoid vaccination if 
there is fever
Mild fever alone should not be criteria to delay vaccination if baby is otherwise stable
Preterm infants cannot tolerate 
multiple vaccines together
To avoid unnecessary delay and multiple hospital visits, it is advisable to give multiple live vaccines in 
a single setting unless; there is inadequate space for multiple simultaneous intramuscular vaccinations. 
There should be at least 4 weeks gap between vaccines for optimal response
BPD: Borderline personality disorder, VPD: Vaccine-preventable diseases, DTaP: Diphtheria, tetanus, and pertussis, Hep B: Hepatitis B, HiB: Haemophilus influenzae type b, 
aP: Acellular pertussis
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dysplasia and gastroesophageal reflux, there is a tendency for 
repeated respiratory tract infections
•	 Preterm	infants	are	more	prone	to	have	rotaviral	diarrhea	as	
compared to term counterparts.
2. What is the difference between vaccine responses between 
preterm neonates and full-term neonates? [15,16,18]
The preterm neonates who had prolonged NICU stay remain 
the most vulnerable group to get affected by VPD due to the 
following reasons:
•	 Less	 than	 adequate	 secretion	 of	 immune	 peptides	 such	 as	
defensin from skin, lungs, and epithelial cells which can alter host 
gene expression, act as cytokines, and/or induce less chemokine 
production and inhibit lipopolysaccharide production
•	 Premature	infants	have	impaired	innate	immune	system	due	
to less functional antigen-presenting cells, thus, resulting in 
suboptimal vaccine uptake
•	 Suboptimal	 adaptive	 and	 cellular	 immunity	 including	 Th1	
and Th2 are also less proficient in premature neonates
•	 Premature	 infants	 have	 predominant	 IgM	 response	 with	
slower or nil switch IgG response after vaccination
•	 Maternal	antibody	levels	as	well	as	 transfer	are	 lower	 than	
term neonates, this is beneficial in the sense it might actually 
facilitate vaccine responses
CURRENT IMMUNIZATION SCHEDULE
The salient features of the recommendation of vaccination of 
preterm infants until 2 years of age by National Immunization 
Schedule (NIS) versus the Indian Academy of Pediatrics (IAP) 
have been summarized in Table 2 [8,20].
The approximate costs and available brands of various other 
vaccines for preterm infants until 2 years of age are summarized in 
Table 3. Wherever parents need to purchase vaccines (which are 
not been given free by the government), they must be informed 
about the cost-benefit ratio.
INDIVIDUAL VACCINES FOR PRETERM INFANTS 
(UNTIL 2 YEARS OF AGE)
Bacillus Calmette Guérin (BCG) Vaccine
BCG can be administered safely and effectively to LBW and 
preterm infants after stabilization and before discharge as it is 
found in previous studies that uptake of BCG vaccine is good in 
premature infants up to 34–35 weeks post-conceptional age [18]. 
Hence, it is a good practice to inject BCG at the time of discharge 
for most of the premature infants.
Polio Vaccine (Oral Poliovirus Vaccines [OPV] and Inactivated 
Polio Vaccine [IPV])
First, oral polio vaccine is to be given before discharge to provide 
herd immunity and help in gut priming. To prevent enteral 
circulation of live poliovirus to other premature sick infants in 
NICU, it is better to avoid giving polio vaccine to infants still 
admitted in NICU. These infants should receive all other routine 
doses of OPV as well as supplementary doses of OPV as per NIS 
in post-discharge period.
Studies have shown that premature infants are capable of 
mounting immune response similar to term infants following 
IPV against all three polio strains [21]. Thus, IPV can be given 
to preterm infants at recommended chronological age either as 
part of NIS (two fractional intradermal doses of 0.1 ml at 6 weeks 
and 14 weeks or a single IM dose of 0.5 ml at 14 weeks) or 
IAP optional schedule (3 IM doses of 0.5 ml each at 6, 10, and 
14 weeks and a booster at 16–24 months) [8,20].
Hepatitis B Vaccine (Hep B)
As hep B remains a major global concern with higher prevalence 
in South Asian regions, including India, it is of utmost importance 
to achieve the maximal protection against perinatal transmission 
by ensuring complete vaccination at birth. Hep B is the only 
vaccine which has shown a significant lower immunogenicity 
in preterm infants as compared to term infants (45–85% vs. 
90–100%) when administered at birth [22,23]. Although birth 
dose of Hep B should be administered any time soon after birth 
in infants >2 kg, due to decreased efficacy in <2 kg weight 
infants in previous studies, it is generally deferred until the age 
of 1 month [22].
Recent studies have shown protective levels of anti-Hbs 
antibody after the 3rd month of life even in preterm neonates 
if they receive the first dose at 30 days of chronological age 
irrespective of birth weight and gestation [24]. Thus, postnatal 
age rather than gestational age or birth weight might be a 
better predictor of vaccine efficacy. Moreover, birth dose can 
be administered at discharge to all these neonates if consistent 
weight gain is achieved. In infants < 2 kg, born to hep B 
positive mother or whose maternal status is unknown, the 
current practice is to give birth dose Hep B as well as hep B 
Ig within 12 h of life, followed by 3 more doses at 1, 2, and 
6 months of age.
Diphtheria Pertussis Tetanus Combination Vaccine
The similar protective antibody response is seen against 
diphtheria, pertussis, and tetanus after vaccination both in 
preterm, LBW and term infants. Much-hyped concern on 
febrile reactions and apnea following DPT vaccination is 
primarily due to whole-cell pertussis component, especially 
when used in extremely LBW (ELBW) infants. In contrast, 
recent research correlates association of apnea to overall 
hemodynamic condition of neonate at vaccination time rather 
LBW. aP vaccine (either in combination or alone) is not 
associated with apnea and bradypnea even in ELBW infants or 
<31 weeks of gestation [7]. At present, IAP also recommends 
the first dose of DPT vaccine alone or in combination in infants 
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at 6 weeks of chronological age irrespective of birth weight or 
gestation [8].
HiB Vaccine
Studies on immunogenicity of Hib vaccine have shown variable 
result. Recent studies show only marginal differences between 
preterm and term infants and most premature infants are 
able to mount acceptable immune response after vaccination 
with primary series followed by booster dose after 32 weeks 
PMA [25,26]. Optimal safety and immunogenicity of Hib vaccine 
are seen in preterm infants in various regimens commencing at 
6–8 weeks of age. As preterm infants younger than 1 year of age 
are at increased risk for invasive H. influenzae diseases, IAP/NIS 
recommends all premature infants to complete the primary series 
with three doses (from 6 to 14 weeks) followed by one booster 
dose at 18–24 months [8].
Rotavirus Vaccine (RV)
Premature infants are vulnerable to suffer from severe rotaviral 
gastroenteritis requiring hospitalization. Therefore, it is 
recommended to give RV at or after discharge from NICU if infant is 
clinically stable with minimum chronological age of 6 weeks [6-8]. 
Studies using Rotarix (Human monovalent live vaccine (RV1) and 
RotaTeq (Pentavalent human-bovine reassortant rotavirus vaccine 
RV5) have shown good efficacy and immunogenicity in premature 
infants [27,28]. The studies are currently lacking for the newly 
licensed Indian vaccine, Rotavac (Indian neonatal rotavirus live 
vaccine, 116 E), and Rotasiil, which have been incorporated in NIS.
Pneumococcal Conjugate Vaccine (PCV)
Invasive pneumococcal disease is seen most commonly in 
young infants (<2 years) and those with chronic diseases. 
Table 2: Brief summary of recommendation of vaccines for young infants (<24 months) for the year 2018–2019
Postnatal age 
(in completed weeks/months)
Vaccines as per NIS Vaccines as per IAP Comments
Birth BCG
OPV 0
Hep B birth dose
BCG
OPV 0
Hep B birth dose
BCG can be given up to 1 year if not given 
earlier
OPV and Hep B birth dose for institutional 
deliveries to be given within 24 h
6 weeks Pentavalent 1 
(DTwP/HiB/Hep B 1)
OPV 1
IPV$ 1
Rotavirus# 1
PCV# 1
Pentavalent 1 
(DTwP or DTaP/HiB/Hep B)
IPV 1
Rotavirus1
PCV1
IPV dose intradermal 0.1 ml at government 
dispensaries
10 weeks Pentavalent 2 
(DTwP/HiB/Hep B 1)
OPV 2
Rotavirus# 2
Pentavalent 2 
(DTwP or DTaP/HiB/Hep B)
IPV 2
Rotavirus2
PCV 2
Bivalent OPV is being used after April 16
14 weeks Pentavalent 3 
(DTwP/HiB/Hep B 1)
OPV-3
IPV$ 2
Rotavirus#3
PCV# 2
Pentavalent 3 
(DTwP or DTaP/HiB/Hep B)
IPV3
Rotavirus3
PCV 3
-
6 months TCV -
9 months Measles/MR# 1
JE 1**
PCV# 3
Vitamin A
MMR1 dose
JE 1
Vitamin A
Vitamin A dose 1 lakh per oral
12 months Hepatitis A&
Influenzae annually@
16–24 months Measles/MR# 2
JE 2**
DPT booster
OPV booster
Vitamin A
MMR2
JE 2
DPT booster
HiB booster
PCV booster
IPV booster
Varicella 1
Vitamin A
Vitamin A dose 2 lakhs per oral
#Phased introduction of rotavirus, PCV vaccine in selected states. $Two doses of fractional intradermal IPV (ID-fIPV) at 6 and 14 weeks. **Given in JE endemic districts. &For 
live attenuated strain single dose sufficient. @Annual influenza (killed vaccine) recommended for age 6 months–5 years. DTaP: Diphtheria, tetanus, and pertussis, BCG: Bacillus 
calmette guérin, OPV: Oral poliovirus vaccines, Hep B: Hepatitis B, HiB: Haemophilus influenzae type b, PCV: Pneumococcal conjugate vaccine, TCV: Typhoid conjugated vaccine, 
IPV: Inactivated polio vaccine, NIS: National Immunization Schedule, IAP: Indian Academy of Pediatrics
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Hence, preterm neonates with chronic respiratory illnesses 
like bronchopulmonary dysplasia remain vulnerable. Although 
preterm infants have lesser antibody levels and immunogenicity 
to several strains of pneumococcal vaccines following primary 
immunization series compared to term infants, the differences 
get nullified after a booster [29-31]. Hence, it is recommended to 
complete three doses of vaccine schedule from 6 to 14 weeks at 
4 weekly intervals followed by a booster at 16–24 months.
Influenza Vaccine
As preterm infants are at increased risk of complicated influenza, 
two doses of inactivated flu virus vaccine may be considered at the 
beginning of flu season in preterm infants after 6 months of age after 
discussion with parents on case to case basis. Along with preterm 
infants, household contacts as well as hospital personnel caring for 
these infants (especially in <6 months of age) should be vaccinated 
as well, with influenza vaccine (cocooning strategy) [32].
Measles Containing Vaccine (Measles Mumps Rubella 
[MMR]/MR)
Passive transfer of antibodies from immunized mother usually 
provides sufficient protection until 6 months of age. However, 
in preterm NICU graduates, maternal antibodies might be 
inadequate to provide immunity. A recent study has shown that 
60% of preterm and 30% of term infants did not show antibodies 
against measles in their serum in early infancy [33]. Another 
study showed that in infants <28 weeks gestation, reduced 
maternally transferred antibodies against measles by as early as 
3 months of age [34]. Hence, it seems rational to immunize all 
preterm neonates against measles as early as possible. However, 
vaccination with MMR/MR at 9 months or earlier has resulted in 
poor seroconversion, and thus booster dose may be required later. 
Considering these facts, IAP recommends routine immunization 
of all preterm neonates with measles-containing vaccine starting 
after 9 months of age which should be followed by two booster 
doses at 16–24 months and 5 years, respectively [8].
Typhoid Vaccine
Due to the continuous burden of typhoid fever, wide prevalence 
of antibiotic-resistant strains of Salmonella typhi as well as the 
availability of safe and effective typhoid vaccines, the WHO 
recommends the use of typhoid vaccines in national programs 
for the control of typhoid fever [35]. Typhoid conjugate vaccine 
(TCV) is the preferred vaccine at all ages over typhoid Vi 
polysaccharide vaccine. Accordingly, IAP endorses a single dose 
Table 3: Available brands and approximate costs of available vaccines in market
Vaccines Commonly used brands Approximate cost in INR
Conjugated pneumococcal vaccines (PCV 10/13) Prevenar (PCV-13) by Wyeth
Synflorix (PCV-13) by GSK
3,800
1,320
Rotavirus vaccine Rotarix (2 doses) by GSK
RotaTeq by MSD
Rotavac by Bharat Biotech
Rotasiil by Sii
1,499
990
689
500
Injectable polio vaccine Imovax Polio vaccine by Sanofi Pasteur (Not available) 483
Hepatitis A (formaldehyde inactivated/live attenuated) Havrix by GSK
Avaxim 80 by Sanofi Pasteur
Biovac A (live attenuated) by Wockhardt
960
1,260
1,290
Influenza (inactivated) FluQuadri by Sanofi Pasteur
Fluarix by GSK Biological
Agripal by Panacea Biotec
Vaxiflu by Zydus Cadila
1,250
599
760
530
TCV Typbar-TCV by Bharat Biotech
Zyvac TCV by Zydus
1,799
1,795
MMR (live inactivated) Trimovax by Aventis Pasteur
Priorix by GSK
Tresivac by Sii
150
545
141
MMR+Chickenpox combination Priorix Tetra by GSK 2,999
Chickenpox Varilrix by GSK
Okavax by Sanofi
Biovac V by Wockhardt
Varivax by Merck
1,560
1,260
1,699
1,200
Pentavalent/Hexavalent combinations Pentavac SD (HiB+DTaP+Hep B) from Sii
Pentaxim (DTaP+HiB+IPV) from Sanofi Pasteur
Hexaxim (DTaP+HiB+Hep B+IPV) – Sanofi Pasteur
Infanrix hexa (DTaP+HiB+Hep B+IPV) by GSK
Easy six (DTaP+HiB+Hep B+IPV) by Panacea Biotec
550
2,495
3,300
2,300
2,100
DTaP: Diphtheria, tetanus, and pertussis, Hep B: Hepatitis B, HiB: Haemophilus influenzae type b, PCV: Pneumococcal conjugate vaccine, TCV: Typhoid conjugated vaccine, 
MMR: Measles mumps rubella, IPV: Inactivated polio vaccine
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of TCV for all infants (including preterm infants) and children 
starting from 6 months of age.
Chickenpox Vaccine
Studies did not show a difference in antibody response to 
chickenpox vaccine among preterm and term infants when 
administered after 1 year of age [36]. IAP recommends varicella 
vaccine to be given between 12 and 23 months of age separately or 
in combination. At present, it is not included in routine schedule.
Palivizumab/Respiratory Syncytial Virus (RSV) Prophylaxis
Although AAP recommends routine RSV immunoprophylaxis 
with RSV monoclonal antibodies for all infants born <29 weeks, 
due to non-availability, high cost, and lack of evidence in Indian 
scenario, it is not being advised routinely to all preterm infants in 
India currently [7].
Immunizing Family Members and Close Contacts (Cocooning)
Immunization of family members and other close contacts, 
including healthcare workers known as cocooning, is an indirect 
protective strategy for vulnerable preterm infants against diseases 
such as influenza and pertussis [37]. This can be achieved by 
active parental involvement and educational counseling.
SOME GENERAL PRECAUTIONS DURING 
VACCINATION OF PREMATURE/LBW INFANTS
1. Since these infants have low muscle mass, use of shorter and 
thinner needles (5/8 inch or less) is recommended
2. For infants who were born as extremely preterm (<28 weeks) 
or very preterm (<32 weeks), it is preferable to give first 
vaccination at hospital and monitor for 48–72 hours 
subsequently before discharge as some of them are likely to 
have apnea or desaturation. However, if such infants have 
already stayed in NICU for more than 2 months and are 
hemodynamically stable (apnoea free, not on caffeine) such 
observations might be omitted [7]. In case of such incident in 
the first dose, the index case should be monitored vigilantly 
while receiving booster doses as well.
CONCLUSION
Based on our review, it can be concluded that all vaccines 
should be administered as per chronological age irrespective 
of birth weight and gestation in preterm NICU graduates with 
exception of hep B vaccine. Due to their intrinsic vulnerability 
to VPD, optional vaccines such as conjugated pneumococcal, 
rotavirus, and influenza vaccine should be offered after 
discussion with parents if resources permit. At present, there 
is no recommendation for using routine RSV prophylaxis in 
Indian scenario. Apart from direct vaccination of preterm infants, 
vaccination of pregnant mothers (passive transfer of antibody 
in antenatal period), household contacts (cocooning effect), and 
exclusive breastfeeding are other important strategies to prevent 
VPD in preterm infants.
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